Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.

The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Biopharma, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Jost Fischer

Contact Details

Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States
Phone	949 354 6499
Website	aeonbiopharma.com

Stock Details

Ticker Symbol	AEON
Exchange	NYSEAMERICAN
Stock Type	Common Stock
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001837607
CUSIP Number	00775E102
ISIN Number	US00791X1000
Employer ID	85-3940478
SIC Code	2834

Key Executives

Name	Position
Jost Fischer	Interim Chief Executive Officer and Chairman
Alex Wilson	Executive Vice President, Chief Legal Officer and Corporate Secretary
Dr. Chad K. Oh M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Apr 21, 2025	8-K	Current Report
Apr 8, 2025	8-K	Current Report
Mar 27, 2025	8-K	Current Report
Mar 24, 2025	10-K	Annual Report
Mar 24, 2025	8-K	Current Report
Mar 10, 2025	SCHEDULE 13G	Filing
Mar 10, 2025	8-K	Current Report
Mar 7, 2025	SCHEDULE 13D/A	Filing
Mar 3, 2025	SCHEDULE 13G	Filing
Feb 28, 2025	UPLOAD	Filing

View All SEC Filings